MAGE-A3-specific anticancer immunotherapy in the clinical practice


Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of recombinant MAGE-A3 and AS15, a multicomponent… (More)



Citations per Year

Citation Velocity: 19

Averaging 19 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@inproceedings{Brichard2013MAGEA3specificAI, title={MAGE-A3-specific anticancer immunotherapy in the clinical practice}, author={Vincent G Brichard and Quentin Godechal}, booktitle={Oncoimmunology}, year={2013} }